Redeye: Xspray Pharma - Shaping up to an exciting year

Report this content

In this update we look at the year ahead with the manufacturing and preparations to take HyNap-Dasa to market. We also update our view regarding the Sprycel, Nexavar and Tasigna market opportunities. We see a strong case in Xspray for the year going forward and reiterate our valuation range with a Base Case of SEK 135.

Read more and download the research update:

Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments.

This is a press release from Redeye - Research Powered Investment Banking.